

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
167th Meeting of the Vaccines and Related Biological Products
Advisory Committee
September 17, 2021
AGENDA

Topic: The committee will meet in open session to discuss Pfizer-BioNTech’s supplemental Biologics License Application for administration of a third dose, or “booster” dose, of the COVID-19 vaccine, Comirnaty, in individuals 16 years of age and older.

Time	Presentation/Presenter
8:30 a.m.	<p><u>Opening Remarks: Call to Order and Welcome (10 min)</u> Arnold Monto, M.D. Acting Chair, VRBPAC Professor of Public Health and Epidemiology, University of Michigan</p> <p><u>Administrative Announcements, Roll Call, Introduction of Committee, Conflict of Interest Statement (20 min)</u> Prabhakara Atreya, Ph.D. Acting Designated Federal Officer, VRBPAC Director, Division Scientific Advisors and Consultants, CBER, FDA</p>
9:00 a.m.	<p><u>FDA Introduction (20 min)</u></p> <p><u>Welcome</u></p> <ul style="list-style-type: none"> • Peter Marks, M.D. Ph.D. Center Director, CBER, FDA <p><u>Introduction of the Topic</u></p> <ul style="list-style-type: none"> • Marion Gruber, Ph.D., Director, Office of Vaccines Research and Review (OVR), CBER, FDA <p><u>Background</u></p> <ul style="list-style-type: none"> • Ramachandra Naik, Ph.D., Biologist (Regulatory), Division of Vaccines and Related Product Applications (DVRPA), OVR, CBER, FDA • Q/A – 5 Min
9:20 a.m.	<p><u>CDC: Epidemiology of pandemic CDC delta variant/breakthrough infections (15 min)</u></p> <ul style="list-style-type: none"> • Sarah Oliver, M.D., M.S.P.H. Centers for Disease Control and Prevention Division of Viral Disease, National Center for Immunization and Respiratory Diseases • Q/A - 5 min <p><u>Real-world effectiveness of COVID-19 vaccines (20 min)</u></p> <ul style="list-style-type: none"> • Jonathan Sterne, B.A., M.Sc., Ph.D. Professor of Medical Statistics and Epidemiology Bristol Medical School, University of Bristol, UK • Q/A – 5 min

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
167th Meeting of the Vaccines and Related Biological Products
Advisory Committee
September 17, 2021
AGENDA

	<p><u>Booster protection against confirmed infections and severe disease – data from Israel (30 min)</u></p> <ul style="list-style-type: none"> • Speaker 1: Sharon Alroy Preis, M.D., M.P.H., M.B.A, Director of Public Health Services, Ministry of Health, Israel • Speaker 2: Ron Milo, Ph.D., Professor, Weizmann Institute, Israel • Q/A – 5 min
10:40 am	<u>BREAK (5 min)</u>
10:45 am	<p><u>Sponsor Presentation (45 Min)</u></p> <p>BNT162b2 [COMIRNATY (COVID-19 Vaccine, mRNA)] Booster (Third Dose)</p> <ul style="list-style-type: none"> • Donna Boyce, MS, Senior Vice President, Global Regulatory Affairs Pfizer Inc. • William C. Gruber, MD, Senior Vice President, Vaccine Clinical Research and Development Pfizer Inc.
11:30 am	<p><u>FDA Presentation (35 min)</u></p> <ul style="list-style-type: none"> • Joohee Lee, M.D., Medical Officer, Clinical Review Branch 1, DVRPA, OVRP, CBER, FDA
12:05 pm	<u>Lunch (25 min)</u>
12:30 pm	<u>Open Public Hearing (60 min)</u>
1:30 pm	<u>Break (10 Min)</u>
1:40 pm	<u>Q & A regarding Sponsor and FDA presentations (45 min)</u>
2:25 pm	<u>Committee Discussion and Voting (120 min)</u>
4:45 pm	<u>Meeting Adjourned</u>